Abbott Laboratories (NYSE:ABT) Issues Earnings Results

Abbott Laboratories (NYSE:ABT) announced its quarterly earnings results on Wednesday. The healthcare product maker reported $1.42 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.42, FiscalAI reports. The firm had revenue of $13.01 billion during the quarter, compared to analysts’ expectations of $12.99 billion. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%.

Abbott Laboratories Price Performance

Shares of NYSE ABT opened at $102.68 on Wednesday. The firm’s 50-day moving average price is $105.68 and its 200-day moving average price is $98.30. Abbott Laboratories has a 1-year low of $81.97 and a 1-year high of $132.02. The firm has a market capitalization of $177.67 billion, a P/E ratio of 33.23, a P/E/G ratio of 1.93 and a beta of 0.59. The company has a current ratio of 1.38, a quick ratio of 0.97 and a debt-to-equity ratio of 0.57.

Abbott Laboratories Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, November 16th. Stockholders of record on Thursday, October 15th will be issued a dividend of $0.63 per share. The ex-dividend date is Thursday, October 15th. This represents a $2.52 annualized dividend and a dividend yield of 2.5%. Abbott Laboratories’s dividend payout ratio is currently 81.55%.

Abbott Laboratories News Summary

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Strong third-quarter performance: Abbott reported 14.5% year-over-year sales growth, or 7.0% on a comparable basis. Adjusted diluted EPS was $1.42, and management reaffirmed its full-year EPS guidance, signaling that operating trends remain on track. Abbott Reports Third-Quarter 2026 Results and Reaffirms Full-Year EPS Guidance
• Positive Sentiment: Nutrition separation could unlock value: Abbott plans to distribute its approximately $8.5 billion Nutrition business to shareholders as an independent, publicly traded company by the end of 2027. Management expects the separation to give Abbott faster sales growth and a broader margin profile, while allowing both businesses to pursue more focused strategies. Abbott Announces Nutrition Business Separation
• Positive Sentiment: Diagnostics expansion: Abbott received European CE Mark authorization for its Cologuard Plus colorectal cancer screening test, expanding the potential market for its diagnostics portfolio in Europe. Abbott Secures Europe CE Mark for Colorectal Cancer Test
• Neutral Sentiment: Execution risk remains: The Nutrition transaction is not expected to be completed until 2027, leaving investors to evaluate separation costs, tax-free distribution requirements and the eventual growth and margin profiles of both companies.
• Negative Sentiment: Libre faces a more competitive market: Abbott’s FreeStyle Libre continuous glucose monitoring business continues to grow, but rising competition, product improvements from rivals and insurer pressures could limit future pricing and profitability. Can Libre Keep Growing as Glucose Monitoring Becomes More Competitive?

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the stock. Wells Fargo & Company boosted their target price on shares of Abbott Laboratories from $109.00 to $112.00 and gave the company an “overweight” rating in a report on Friday, July 17th. Robert W. Baird assumed coverage on Abbott Laboratories in a report on Wednesday, July 1st. They set an “outperform” rating and a $121.00 price target for the company. BTIG Research lifted their price objective on Abbott Laboratories from $131.00 to $134.00 and gave the stock a “buy” rating in a research report on Friday, July 17th. Royal Bank Of Canada reissued an “outperform” rating and issued a $130.00 price objective on shares of Abbott Laboratories in a research note on Friday, July 17th. Finally, Barclays assumed coverage on Abbott Laboratories in a research note on Wednesday, October 7th. They issued an “overweight” rating and a $120.00 price objective on the stock. Three equities research analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat, Abbott Laboratories has an average rating of “Moderate Buy” and a consensus price target of $118.88.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company that develops, manufactures and markets a broad range of medical products and services. Founded in 1888 by Wallace C. Abbott, the company is headquartered in Abbott Park, Illinois, and serves patients, healthcare providers and consumers in markets around the world.

Abbott operates across four principal businesses: medical devices, diagnostics, nutrition and established pharmaceutical products. Its offerings include glucose-monitoring systems such as FreeStyle Libre; cardiovascular devices, including stents and structural heart products; laboratory and point-of-care diagnostic systems; and branded generic medicines in areas such as gastroenterology, women’s health and cardiometabolic care.

The company’s nutrition portfolio includes infant and pediatric products such as Similac and PediaSure, adult nutritional products such as Ensure, and rehydration products such as Pedialyte.